Peptides · Peptide comparison
Exenatide vs Liraglutide
First-in-class GLP-1 receptor agonist derived from Gila monster venom (Byetta/Bydureon), FDA-approved for type 2 diabetes with demonstrated cardiovascular safety in the 14,752-patient EXSCEL trial and available in both twice-daily and once-weekly formulations
FDA-approved once-daily GLP-1 receptor agonist (Victoza/Saxenda) that reduces HbA1c by 0.9–1.6%, promotes 5–10% body weight loss, and demonstrated a 13% reduction in major adverse cardiovascular events in the landmark LEADER trial of 9,340 patients
- Weight Management
- Weight Management
At a glance
Quick comparison
Efficacy
Benefit ratings
Blood Sugar Control
Weight Loss
Heart Safety
Weight Management
Metabolic
Healing & Recovery
Technical data
Compound specifications
Exenatide
- Molecular formula
- C184H282N50O60S
- Molecular weight
- 4,187 Da
- Half-life
- Byetta: ~2.4 hours (immediate-release); Bydureon: ~7 weeks effective duration via PLGA microsphere technology; Tmax ~2.1 hours (Byetta)
- Bioavailability
- 65–75% after subcutaneous injection (Byetta); microsphere sustained release for Bydureon
- CAS number
- 183321-74-6
Liraglutide
- Molecular formula
- C172H265N43O51
- Molecular weight
- 3,751 Da
- Half-life
- ~13 hours (enabling once-daily dosing); Tmax 8–12 hours; steady state in 3–5 days
- Bioavailability
- ~55% after subcutaneous injection; >98% plasma protein binding to albumin via C16 fatty acid moiety
- CAS number
- 204656-20-2
Protocols
Dosing compared
Exenatide
Subcutaneous
- 5 mcgTwice daily, within 60 minutes before the two main meals · First 1 monthFDA-labeled starting dose for immediate-release Byetta to assess tolerability before escalating [6].
- 10 mcgTwice daily, within 60 minutes before the two main meals · OngoingFDA-labeled maintenance dose for immediate-release Byetta after 1 month at the starting dose [6].
- 2 mgOnce weekly · Ongoing chronic therapyExtended-release exenatide (Bydureon) FDA-labeled at 2 mg once every 7 days; convenient weekly alternative to twice-daily dosing [7]. Once-weekly exenatide has cardiovascular outcome data [1].
Liraglutide
Subcutaneous
- Week 10.6 mgOnce daily · Week 1FDA-label starting dose for both Victoza (type 2 diabetes) and Saxenda (weight management); used for the first week to improve GI tolerability before escalation [6].
- Ongoing1.2-1.8 mgOnce daily · OngoingVictoza maintenance range for type 2 diabetes; dose increased to 1.2 mg after week 1 and to 1.8 mg if further glycemic control is needed [6].
- Ongoing3.0 mgOnce daily · OngoingSaxenda maintenance dose for chronic weight management, reached by escalating 0.6 mg weekly (0.6 to 1.2 to 1.8 to 2.4 to 3.0 mg over 5 weeks) [6].
Applications
Best suited for
Exenatide
- Type 2 diabetes patients inadequately controlled on metformin seeking add-on therapy with weight loss benefit
- Exenatide is particularly well-suited for individuals focused on type 2 diabetes patients inadequately controlled on metformin seeking add-on therapy with weight loss benefit. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach [5].
- Patients preferring once-weekly dosing convenience (Bydureon 2 mg) over daily injections for improved adherence
- Exenatide is particularly well-suited for individuals focused on patients preferring once-weekly dosing convenience (bydureon 2 mg) over daily injections for improved adherence. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach [7].
- Overweight or obese type 2 diabetes patients (BMI >27) requiring glycemic control without weight gain
- Exenatide is particularly well-suited for individuals focused on overweight or obese type 2 diabetes patients (bmi >27) requiring glycemic control without weight gain. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach [4].
- Patients with established cardiovascular disease who need a GLP-1 RA with demonstrated cardiovascular safety
- Exenatide is particularly well-suited for individuals focused on patients with established cardiovascular disease who need a glp-1 ra with demonstrated cardiovascular safety. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Liraglutide
- Type 2 diabetes patients with HbA1c >7% requiring both glycemic control and weight management
- Liraglutide is particularly well-suited for individuals focused on type 2 diabetes patients with hba1c >7% requiring both glycemic control and weight management. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach [3].
- Obese individuals (BMI ≥30) or overweight (BMI ≥27) with weight-related comorbidities seeking FDA-approved pharmacotherapy
- Liraglutide is particularly well-suited for individuals focused on obese individuals (bmi ≥30) or overweight (bmi ≥27) with weight-related comorbidities seeking fda-approved pharmacotherapy. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach [6].
- Patients with established cardiovascular disease or high cardiovascular risk seeking cardioprotective diabetes therapy
- Liraglutide is particularly well-suited for individuals focused on patients with established cardiovascular disease or high cardiovascular risk seeking cardioprotective diabetes therapy. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach [7].
- Patients on metformin requiring add-on therapy with favorable weight and cardiovascular profile
- Liraglutide is particularly well-suited for individuals focused on patients on metformin requiring add-on therapy with favorable weight and cardiovascular profile. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach [3].
Safety profile
Side effects
Exenatide
Common
- Nausea
- Vomiting and diarrhea
- Injection site nodules (Bydureon)
- Decreased appetite and constipation
Uncommon
- Hypoglycemia
Serious
- Acute pancreatitis
- Renal impairment
Liraglutide
Common
- Nausea
- Diarrhea
- Vomiting
- Decreased appetite and headache
Uncommon
- Injection site reactions
Serious
- Acute pancreatitis
- Gallbladder disease
Research status
Safety & evidence
Exenatide
- Evidence level
- Strong human trials (Phase 3 or FDA approved)
- FDA status
- FDA approved for this use
- Safety overview
- Exenatide is an FDA-approved GLP-1 receptor agonist with post-market safety data spanning 15+ years, though some safety concerns have emerged. Nausea affects 30-45% of patients, [6] dose-dependent and typically improves within 1-2 weeks but can lead to treatment discontinuation in 5% of patients. Pancreatitis risk, while rare (0.1-0.2%), is increased and contraindicated in patients with history of acute pancreatitis. Benign thyroid C-cell adenomas were seen in rats across all exenatide doses in a 104-week carcinogenicity study, but this appears only in the Nonclinical Toxicology section: the immediate-release label (Byetta) carries no boxed warning and does not contraindicate medullary thyroid cancer or MEN 2. That contraindication belonged to extended-release Bydureon, which no longer has a current US label. Acute kidney injury has been reported in 0.3-1% of patients, particularly with concurrent NSAID or ACE inhibitor use. Hypoglycemia risk is minimal when used as monotherapy but increases substantially when combined with insulin or sulfonylureas.
Contraindications
- Prior serious hypersensitivity reaction to exenatide or any excipient [6]
- Extended-release exenatide only (Bydureon, now withdrawn in the US): personal or family history of medullary thyroid carcinoma (MTC) or MEN 2. The immediate-release label carries no such contraindication and no boxed warning [6][7].
Liraglutide
- Evidence level
- Strong human trials (Phase 3 or FDA approved)
- FDA status
- FDA approved for this use
- Safety overview
- Liraglutide (Victoza, Saxenda) is FDA-approved with extensive safety data from 15+ years of clinical use in diabetes (GLP-1 agonist) and obesity indications. Gastrointestinal side effects (nausea, vomiting, diarrhea) occur in 30-40% of patients during dose escalation [6] but diminish significantly after 2-3 weeks of stable dosing. Black box warnings include risk of medullary thyroid carcinoma and pancreatitis, though absolute incidence remains rare. Injection site reactions are minimal. The compound shows no hepatotoxicity, nephrotoxicity, or major drug interactions at approved doses.
Contraindications
- Personal or family history of medullary thyroid carcinoma (MTC) — black box warning based on rodent thyroid C-cell tumor findings [6]
- Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) [6]
- Known hypersensitivity to liraglutide or any excipients [6]
Decision guide
Which is right for you?
Exenatide
Choose Exenatide if…
- Type 2 diabetes patients inadequately controlled on metformin seeking add-on therapy with weight loss benefit
- Patients preferring once-weekly dosing convenience (Bydureon 2 mg) over daily injections for improved adherence
- Overweight or obese type 2 diabetes patients (BMI >27) requiring glycemic control without weight gain
- Patients with established cardiovascular disease who need a GLP-1 RA with demonstrated cardiovascular safety
Liraglutide
Choose Liraglutide if…
- Type 2 diabetes patients with HbA1c >7% requiring both glycemic control and weight management
- Obese individuals (BMI ≥30) or overweight (BMI ≥27) with weight-related comorbidities seeking FDA-approved pharmacotherapy
- Patients with established cardiovascular disease or high cardiovascular risk seeking cardioprotective diabetes therapy
- Patients on metformin requiring add-on therapy with favorable weight and cardiovascular profile